The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at Rs.130 for a unit of 10 capsules.
Cipla’s petition to the Department of Industrial Policy & Promotion (DIPP) to revoke the Novartis patents on Indaceterol is available here.
In a new development, Novartis filed a trademark infringement case against Cipla in the Delhi High Court on the ground that Cipla’s brandname UNIBREZ – for Indaceterol – was confusingly similar to its brandname Onbrez. The matter – NOVARTIS A.G., AND ANR Vs. CIPLA LTD, CS(OS) 3356/2014 – was heard and dismissed on 17th November 2014 as Cipla agreed to amend its brandname.